Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in ...

Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $43 from $31 and keeps an Equal Weight rating on the shares. The ...

In a report released on November 8, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

Hyperion Munitions produces an innovative enhancement for the AR-15’s mil-spec trigger design that allows for custom tuning ...

Q4 2024 Earnings Conference Call November 6, 2024 5:00 PM ETCompany ParticipantsMatt Shimao - Head of Investor RelationsNeil Barua ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

BOSTON, Nov. 6, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that its Board of Directors has authorized the repurchase of up to $2 billion worth of PTC common stock through September 30 ...

Good afternoon, ladies and gentlemen, and thank you for standing by, and welcome to today's PTC 2024 fourth-quarter conference call. (Operator Instructions) I would now like to turn the call over ...

The biopharmaceutical company posted revenue of $196.8 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $173.5 million. PTC Therapeutics expects full-year ...